The MLL gene in chromosome band 11q23 is frequently rearranged in acute lymphoblastic and acute myeloid leukemias. To date, more than 50 different chromosomal regions are known to participate in translocations involving 11q23, many of which affect MLL. The pathogenetically important outcome of these rearrangements is most likely the creation of a fusion gene consisting of the 5Ј part of the MLL gene and the 3Ј end of the partner gene. Although abnormalities of the MLL gene as such are generally associated with poor survival, recent data suggest that the prognostic impact varies among the different fusion genes generated. Hence, detection of the specific chimeric gene produced is important for proper prognostication and clinical decision making. We have developed a paired multiplex reverse-transcriptase polymerase chain reaction analysis to facilitate a rapid and accurate detection of the most frequent MLL fusion genes in adult and childhood acute leukemias. To increase the specificity, two sets of primers were designed for each fusion gene, and these paired primer sets were run in parallel in two separate multiplex one-step PCR reactions. Using the described protocol, we were able to amplify successfully, in one single assay, the six clinically relevant fusion genes generated by the t(4;11)(q21;q23) [ 
Introduction
Abnormalities of the MLL (ALL-1, HRX, HTRX1) gene in chromosome band 11q23 are frequent in de novo acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as in therapy-related myeloid malignancies occurring after previous treatment with DNA topoisomerase II inhibitors. [1] [2] [3] [4] The MLL gene consists of 37 exons (e), with most rearrangements occurring in an 8.3 kb segment -the breakpoint cluster region (bcr) -that includes e8-14 [5] [6] [7] [8] [9] (e5-11 according to Gu et al 7 ) . To date, more than 50 translocations involving 11q23 have been described in various hematologic malignancies. 10 Many of these rearrangements involve the MLL gene, and so far close to 20 partner genes have been cloned. 4 The most fre- 3, 10 Both these rearrangements occur predominantly in children and are associated with a poor prognosis, at least in infants. 4, [11] [12] [13] [14] In AML, the most common abnormalities are t(6;11)(q27;q23) [MLL/AF6], t(9;11)(p21-22;q23) [MLL/AF9], t(10;11)(p11-13;q23) [MLL/ AF10], and t(11;19)(q23;p13.1) [MLL/ELL] which affect both children and adults. 10, 12, [15] [16] [17] The prognostic implications of these rearrangements vary. The t(9;11) has generally been associated with a more favorable outcome, [17] [18] [19] whereas the t(6;11) and t(11;19) confer a poor prognosis; 12, 15, 20 the available data on the prognostic impact of t(10;11) are conflicting. 16, 21 Detection of 11q23/MLL rearrangements is hence of importance for a proper prognostication and clinical decision-making.
Various methods are available for detecting 11q23/MLL abnormalities, but they all have their disadvantages. Chromosome banding analyses are time-consuming and dependent on good chromosome morphology. Interphase fluorescence in situ hybridization (FISH) and Southern blot analyses can be used to reveal if MLL is rearranged but do not provide any information on the specific fusion gene generated. 9, [22] [23] [24] Reverse-transcriptase polymerase chain reaction (RT-PCR) analysis of specific chimeric genes is rapid, and furthermore, by using real-time PCR, quantitative data may be obtained. [25] [26] [27] However, the detection of commonly occurring fusion genes with separate PCR reactions is labor-intensive. For this reason, multiplex-PCR analyses enabling the detection of several different fusion genes in one or a few reactions have been developed. [28] [29] [30] [31] Here, we describe a paired multiplex RT-PCR (PMRT-PCR) assay, which for the first time, allows rapid and accurate detection of the clinically relevant fusion genes MLL/AF4, MLL/AF6, MLL/AF9, MLL/AF10, MLL/ENL, and MLL/ELL in one single assay.
Materials and methods

Cell lines and patient samples
The following five cell lines were used: MV4;11 for MLL/AF4, ML-2 for MLL/AF6, and Mono-Mac 6 for MLL/AF9, obtained from the German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany, and cell pellets from KOCL-33 and KOPN-1 with the MLL/ENL, kindly provided by Dr ) without cytogenetic evidence of 11q23 abnormalities were also analyzed using the protocol described.
RNA preparation and cDNA synthesis
Total RNA was prepared using the TRIzol reagent kit (GibcoBRL, Life Technologies) according to the manufacturer's instructions. Five g of total RNA were reversely transcribed to cDNA in a final volume of 20 l, using random hexamer primers and Moloney murine leukemia virus reverse transcriptase (M-MLV RT; GibcoBRL, Life Technologies) as previously described. 40 To detect a possible contamination in the cDNA synthesis, a sample with water as template was always included. In addition, cDNA was prepared from cell lines without evidence of cytogenetic 11q23 abnormality. The integrity of the RNA and cDNA was examined in a separate PCR by amplifying a fragment of the ABL gene, as described. 
PMRT-PCR analysis and construction of primers
All primers were designed using the Oligo program (version 5.0) (National Bioscience, Inc, Plymouth, MN, USA), and gene sequences were retrieved from GeneBank (Table 3) . Oligonucleotide primers were purchased from Life Technologies. Two individual reaction mixtures, one out-and one in-mix, were designed to allow the simultaneous detection of the six fusion genes in two parallel one-step multiplex PCR reactions. Each mix contained a single 5Ј MLL-specific primer located in e8, in combination with a set of 3Ј primers specific for the different fusion genes analyzed ( Figure 1 ). In order to optimize the PCR protocol, various annealing temperatures, PCR-buffer concentrations, MgCl 2 concentrations, as well as different primer combinations were tested. In the final protocol, the following primers were used: the 'out-mix' primers 3759U, 1607L, 439L, 1825L, 1049L, 2366L, 247L, 216L, 1399L, and the 'in-mix' primers 3920U, 1569L, 351L, 1645L, 1017L, 2316L, 170L, 91L, and 1327L ( Figure 1 and Table 3 ). The PCR amplifications were performed in 50 l reaction mixtures consisting of 0.8 mM dNTP, 1.25 mM MgCl 2 (the in-mix contained 1.75 mM MgCl 2 ), 1 × PCR-buffer (the out-mix contained 1.1 × PCR-buffer), 0.5 M of each primer, 1 U Platinum enzyme (GibcoBRL, Life Technologies), and 2 l cDNA template. In order to identify false positive results, negative cDNA control samples as outlined, as well as a sample with water serving as template, were included in all PCR reactions. The 1295  Table 3 Primer sequences and GeneBank accession numbers Primer Gene Reference sequence or Sequence 5Ј → 3Ј GeneBank accession No.   3759U  MLL  NMF005933  CCC AAA GAA AAG CAG TAG TGA  3920U  MLL  NMF005933  CTC AGC CAC CTA CTA CAG GAC  1569L  AF4  NMF005935  TTT GGT TTT GGG TTA CAG AAC  1607L  AF4  NMF005935  TTT GTA GGG AAA GGA AAC TTG  351L  AF6  NMF005936  GAT AAC CCC TTC TTT TTC CTG  439L  AF6  NMF005936  TTC CCG ATC ATC TTT GTT C  1645L  AF9  NMF004529  AGC GAG CAA AGA TCA AAA TC  1825L  AF9  NMF004529  GAT TTG CTT TGC TTT ATT 
Direct sequencing
The PCR fragments obtained were excised from the gel and purified using the QIAquick gel extraction kit protocol (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Direct sequencing of the purified DNA was performed with the Big Dye sequencing kit (Applied Biosystems, Warrington, UK) in an ABI PRISM 377 DNA sequencer (Applied Biosystems).
Results
PMRT-PCR on cell lines
Using the developed PMRT-PCR protocol, gene fusions of the expected sizes were detected in all cell lines analyzed, and sequencing of the amplified products from the out-mix confirmed the specificity of the assay (Table 1 , Figures 2a and  3a) . All fusion transcripts, except the alternatively spliced MLL e8/AF6 nt 106 detected in the ML-2 cell line, resulted in maintained open reading frames. The alternatively spliced variant in ML-2 produced a transcript with an altered reading frame, resulting in a stop codon 42 nt downstream of the fusion point.
PMRT-PCR on AML and ALL with and without 11q23 rearrangements
To validate the protocol, a total of seven acute leukemias with translocations involving 11q23 were analyzed ( Table 2 , Figures 2a and 3a) . Sequencing of the PCR product from the outmix obtained in case 1 was consistent with a fusion of MLL Leukemia e10 to AF4 at nt 1504 (e5), 41 (also referred to as site B), 37 yielding a fragment of 584 bp. The amplified product from the out-mix obtained in case 2 was sequenced, revealing that MLL e9 was fused to AF4 at nt 1459 (e4, site A), 37, 41 resulting in a 497 bp fragment. In case 3, the sequenced product from the out-mix was consistent with a fusion of MLL e9 to AF9 at nt 1321 (site A), 37 resulting in an 852 bp fragment. Double bands were detected in cases 4 and 5, indicating alternative splicing. Sequence analysis of the amplified fragments from the outmix in case 4, revealed that MLL e10 and e11 were fused to AF10 at nt 883, resulting in fragments of 647 bp and 761 bp, respectively. In case 5, only the smaller, strongly amplified product obtained from the out-mix, was sequenced and shown to be a fusion of MLL e10 to AF10 at nt 979, resulting in a 551 bp fragment. The larger, less strongly amplified fragment of approximately 680 bp (expected 665 bp) using the out-mix, and of approximately 480 bp (expected 469 bp) using the in-mix was not sequenced, but indicated a fusion of MLL e11 to the same AF10 breakpoint. The sequenced PCR product from the out-mix in case 6 revealed a fusion of MLL e9 to ELL at nt 148, yielding a 447 bp fragment. Finally, sequencing of the product obtained from the out-mix in case 7 was consistent with a fusion of MLL e10 to ENL at nt 13 (site A), 37 resulting in a 663 bp fragment. All sequenced fusion transcripts maintained open reading frames. Furthermore, a split-out reaction, in which each case was reamplified with primers for the specific fusion genes, yielded products of the same sizes as in the PMRT-PCR (data not shown).
Eight hematologic malignancies and two cell lines without cytogenetic evidence of 11q23 rearrangements were also analyzed; no fusion transcripts were detected in any of the cases (Figures 2b and 3b) .
Discussion
Multiplex PCR assays for various leukemia-associated translocations have previously been reported, but none of them have described a protocol making it possible to detect the clinically important fusion genes MLL/AF4, MLL/AF6, MLL/AF9, MLL/AF10, MLL/ENL, and MLL/ELL in one assay. [28] [29] [30] [31] To this end, we developed a paired multiplex RT-PCR (PMRT-PCR)
Figure 1
Breakpoints and primer positions of the genes included in the multiplex assay. Vertical arrows indicate nucleotides, the numbers of which are given above, at which the gene is interrupted. The capital letters in parentheses follow the nomenclature suggested by Yamamoto et al. 37 Horizontal arrows indicate positions of primers. Primers included in the out-mix are in bold, whereas those included in the in-mix are given in italics (numbers indicates the position of the first nucleotide of each primer given in 5Ј → 3Ј direction). Nucleotide numbering is according to the GeneBank accession numbers given within parentheses of each gene.
method, by which all these six chimeric genes could be accurately detected.
To our knowledge, only two previous studies have reported multiplex PCR assays for the detection of MLL fusion genes. 28, 29 In the first study described, the MLL/AF4, MLL/AF6, MLL/AF9 and MLL/ENL fusion genes were included in the assay. 28 In the second report, three different multiplex PCR reactions had to be used to detect the six clinically important fusion genes described in this study. 29 In contrast to the studies described above, our strategy applies two separate primer pairs, for each fusion gene, that are used in two parallel one-step multiplex PCR reactions. This is of importance diagnostically because both reactions, with few exceptions (see below), should result in specific fragments if a fusion gene is present. Thus, each sample is in essence tested twice for the presence of a specific MLL fusion gene. Moreover, the out-and in-mixes are designed in such a way that the former always produces a significantly larger PCR fragment than the latter, which further increases the specificity of the assay. We have also chosen not to use a twostep (nested) PCR protocol, given the accumulating data that MLL fusion genes may be present at low levels in healthy individuals. 42 Although the breakpoints in MLL mainly occur in the bcr (8) (9) (10) (11) (12) (13) (14) , 5 predominantly after e8-11, MLL is frequently alternatively spliced. 5, 43, 44 In addition, the partner genes involved in the rearrangements often exhibit multiple breakpoints, resulting in PCR products of variable sizes. Thus, it is not possible to predict which fusion gene is present based on the sizes of the amplified fragments. Consequently, if fragments are obtained after the PMRT-PCR analysis, split-out reactions with the fusion-specific primer pairs only have to be performed in order to identify the specific fusion gene. However, with the exception of infant ALL, this will happen rarely in clinical practice, given the relatively low overall incidence (5-10%) of MLL rearrangements in older children and adults. 45 To date, three different breakpoints in the AF4 gene -nt 1459 (e4, site A), 1504 (e5, site B), and nt 1591 (e6, site C) -have been described, with the most common fusion being between MLL e9 and AF4 at nt 1459 (e4).
6,7,32,41,46-50 In this study, we analyzed two ALL with t(4;11)(q21;q23) ( Table 2) : case 1 showed an MLL e10/AF4 nt 1504 (e5, site B) fusion, whereas case 2 displayed an MLL e9/AF4 nt 1459 (e4, site A) fusion, both of which are consistent with other published MLL/AF4 fusion genes. 32, 47, 49 The infrequent breakpoint at nt 1591 (e6, site C), which accounts for a small fraction (Ͻ10%) of the described fusion genes detected in MLL/AF4 positive leukemias, 51 is located between the internal and external primer pair. Hence, an amplified fragment will only become detectable using the out-mix.
The exons 8, 9 and 10 of the MLL gene are consistently fused to nt 106 of the AF6 gene. 33, 52, 53 Unfortunately, no patient material with a t(6;11)(q27;q23) was available, but analysis of the ML-2 cell line, harboring this translocation, accurately detected an MLL e9/AF6 fusion, as also previously described in this cell line. 33 Four different breakpoints -nt 616 (site C), 1321 (site A), 1627 (site B), and nt 1699 (site D) -have, to date, been found in the AF9 gene. 37, 46, [53] [54] [55] [56] In the present case 3 (Table 2) , with a t(9;11)(p21-p22;q23), a fusion of MLL e9 to AF9 at nt 1321 (site A) was found. This specific MLL fusion is frequent. 37, 54, 56 It should be stressed that the infrequent breakpoint in site D, which was recently described, 55 occurs between our internal and external primer pairs and can hence only be detected by the external pair.
The AF10 gene displays a great breakpoint diversity. To date, seven different breakpoints have been reported; nt 587, 787, 883, 979, 1931, 2110, and 2222. [57] [58] [59] [60] To be able to detect all these variants, four primer pairs were designed and Leukemia placed between nt 979 and 1931, and 3Ј of nt 2222. Two cases (Table 2 ) with t(10;11)(p11-13;q23) were analyzed and both showed double bands after amplification, indicating alternative splicing. The amplified products in case 4 corresponded to a fusion of MLL e10 and 11 to AF10 at nt 883. The latter fusion was highly expressed, whereas the alternatively spliced MLL e10/AF10 transcript was less expressed. The fusion transcripts in case 5 involved the same MLL exon as case 4, but differed in the AF10 breakpoint. Only the smaller, strongly amplified fragment was sequenced, showing that MLL e10 was fused to AF10 at nt 979. The simultaneous occurrence of MLL e9 and 10 fused to AF10 has been described previously, 59 but to the best of our knowledge, not MLL e10 and 11. In the present study, no cases with an MLL/AF10 nt 1931, 2110, or 2222 fusion were available.
Two fusion points -nt 13 (site A) and nt 1111 (site B) -have been reported for the ENL gene. 8, [35] [36] [37] 61, 62 Due to the large distance (1.1 kb) between these two breakpoints, more than one primer pair was needed for the detection of the chimeric MLL/ENL transcripts. The ELL gene, on the other hand, shows a consistent breakpoint at nt 148. 63, 64 We analyzed two leukemias (cases 6 and 7, Several different methods are currently in use to detect 11q23/MLL rearrangements. Although our PMRT-PCR protocol, in principle, could be used as a single method to screen for possible MLL fusion genes, we believe that alternative methods, such as cytogenetic, Southern blot, and FISH analyses, are important complementary methods in the clinical diagnostic work. Thus, any signs of 11q23/MLL rearrangement detected by either method should, as far as possible, be confirmed using alternative methods, not the least because of inherent limitations associated with each method, as well as the important clinical ramifications of rearrangements involving MLL in hematologic malignancies.
In conclusion, the one-step multiplex assay reported herein makes it possible to identify rapidly and accurately six clinically important chimeric genes involving MLL. Although other MLL-translocation partners have been found, eg 1p32, 2p21, 5q31, 3p13, and 15q15, 65 their prognostic impact is still unclear. However, the present PMRT-PCR analysis may be expanded to include additional relevant fusion genes if needed.
